GPP
Great Point Partners Portfolio holdings
AUM
$154M
1-Year Return
2.36%
This Quarter Return
+3.13%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$331M
AUM Growth
-$191M
(-37%)
Cap. Flow
-$195M
Cap. Flow
% of AUM
-58.77%
Top 10 Holdings %
Top 10 Hldgs %
59.58%
Holding
38
New
5
Increased
3
Reduced
19
Closed
9
Top Buys
| 1 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$12.6M |
| 2 |
Viridian Therapeutics
VRDN
|
$5.69M |
| 3 |
Unicycive Therapeutics
UNCY
|
$3.49M |
| 4 |
ProMIS Neurosciences
PMN
|
$3.49M |
| 5 |
Cartesian Therapeutics
RNAC
|
$3.22M |
Top Sells
| 1 |
Arcellx
ACLX
|
$32.7M |
| 2 |
UroGen Pharma
URGN
|
$27.3M |
| 3 |
Evolus
EOLS
|
$20.8M |
| 4 |
Insmed
INSM
|
$16.8M |
| 5 |
Amicus Therapeutics
FOLD
|
$14.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
ProMIS Neurosciences
PMN
$22.3M
| $3.49M | 1.03% |
+2,790,698
| New | +$3.49M |
|
|
27
Cartesian Therapeutics
RNAC
$260M
| $3.22M | 0.95% |
+200,000
| New | +$3.22M |
|
28
VistaGen Therapeutics
VTGN
$111M
| $2.03M | 0.6% |
674,075
-855,263
| -56% | -$2.57M |
|
|
CLYM
29
Climb Bio, Inc. Common Stock
CLYM
$158M
| $1.26M | 0.37% |
+248,168
| New | +$1.26M |
|
30
AnaptysBio
ANAB
$590M
| – | – |
-25,000
| Closed | -$627K |
|
31
Esperion Therapeutics
ESPR
$510M
| – | – |
-5,791,594
| Closed | -$12.9M |
|
|
32
Amicus Therapeutics
FOLD
$2.47B
| – | – |
-1,495,500
| Closed | -$14.8M |
|
|
33
Insmed
INSM
$30.1B
| – | – |
-250,000
| Closed | -$16.8M |
|
34
Lexicon Pharmaceuticals
LXRX
$389M
| – | – |
-30,000
| Closed | -$50.4K |
|
35
Puma Biotechnology
PBYI
$257M
| – | – |
-1,486,544
| Closed | -$4.85M |
|
36
Spyre Therapeutics
SYRE
$1.03B
| – | – |
-134,612
| Closed | -$3.16M |
|
37
Terns Pharmaceuticals
TERN
$618M
| – | – |
-1,149,406
| Closed | -$7.83M |
|
38
Kyverna Therapeutics
KYTX
$157M
| – | – |
-499,152
| Closed | -$3.74M |
|